Baird Downgrades Signify Health to Neutral, Raises Price Target to $30.5
Baird analyst Vikram Kesavabhotla downgrades Signify Health (NYSE:SGFY) from Outperform to Neutral and raises the price target from $28 to $30.5.
JP Morgan Downgrades Apollo Comml Real Est to Underweight, Lowers Price Target to $11
JP Morgan analyst Richard Shane downgrades Apollo Comml Real Est (NYSE:ARI) from Neutral to Underweight and lowers the price target from $12.5 to $11.
JP Morgan Downgrades Ciena to Neutral, Lowers Price Target to $45
JP Morgan analyst Samik Chatterjee downgrades Ciena (NYSE:CIEN) from Overweight to Neutral and lowers the price target from $62 to $45.
AI Is Necessary But Time-Consuming Model Transition, Analyst Says While Downgrading C3.ai
Needham analyst Mike Cikos downgraded C3.ai, Inc (NYSE:AI) to Hold from Buy and removed his last $20 price target. C3.AI announced a shift…
Needham Downgrades C3.ai to Hold
Needham analyst Mike Cikos downgrades C3.ai (NYSE:AI) from Buy to Hold.
Seaport Global Downgrades Tilly’s to Neutral
Seaport Global analyst Mitch Kummetz downgrades Tilly's (NYSE:TLYS) from Buy to Neutral.
Credit Suisse Downgrades Forma Therapeutics Hldgs to Neutral, Announces $20 Price Target
Credit Suisse analyst Tiago Fauth downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Neutral and announces $20 price target.
HC Wainwright & Co. Downgrades Forma Therapeutics Hldgs to Neutral, Lowers Price Target to $20
HC Wainwright & Co. analyst Robert Burns downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Buy to Neutral and lowers the price target from $53 to $20.
Oppenheimer Downgrades Forma Therapeutics Hldgs to Perform
Oppenheimer analyst Mark Breidenbach downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Perform.